Blog

Nelson Advisors has been referenced in the German publictaion M&amp;A Review: Buy &amp; Build im Healthtech – Warum platform deals das digital health M&amp;A prägen.Source: <a href="https://ma-review.de/artikel/buy-build-im-healthtech-warum-plattform-deals-das-digital-health-ma-praegen" data-mce-href="https://ma-review.de/artikel/buy-build-im-healthtech-warum-plattform-deals-das-digital-health-ma-praegen">https://ma-review.de/artikel/buy-build-im-healthtech-warum-plattform-deals-das-digital-health-ma-praegen</a>M&amp;A Review: Buy &amp; Build im Healthtech – Warum platform deals das digital health M&amp;A prägen'Im Digital-Health-Sektor steht die Plattformstrategie im Mittelpunkt aller M&amp;A-Aktivitäten, die darauf abzielt, Ankersysteme wie Electronic Health Record (EHR)-Systeme und technische Vernetzungslösungen gezielt mit KI-Modulen, Remote-Care-Lösungen und Abrechnungsmanagementsystemen zu verbinden.'(5) HealthTech M&amp;A Multiples June 2025: Current Trends and Variables driving valuations<a href="https://nelsonadvisors.co.uk/blog/healthtech-m-a-multiples-june-2025--current-trends-and-variables-driving-valuations">https://nelsonadvisors.co.uk/blog/healthtech-m-a-multiples-june-2025--current-trends-and-variables-driving-valuations</a>'Die Plattform-Strategie im Digital-Health-Sektor gewinnt durch einzigartige Markt- und Regulierungstreiber an Dynamik und steht erst am Anfang ihrer potenziellen Wertschöpfung. Die M&amp;A-Aktivitäten 2025 untermauern die zuvor skizzierte Logik: Erfolgreiche Käufer suchen gezielt nach komplementären Add-ons, um diese in ihre stabilen, hoch bewerteten Ankersysteme (EHR/RCM) zu integrieren. Dies ist der zentrale Unterschied zu generischen Buy-and-Build-Strategien in anderen Sektoren.Auch in naher Zukunft werden strategische Käufer weiterhin spezialisierte Assets suchen, die zur Komplettierung der drei zentralen Strategien dienen. Diese umfassen insbesondere: Interoperabilitäts-Hubs (wie etwa Redox oder InterSystems HealthShare) als Basis für die Reichweiten-Strategie und den reibungslosen Datenfluss; KI-Module (wie Viz.ai oder Aidoc) zur Steigerung der diagnostischen Effizienz im Rahmen der Automatisierungsstrategie, und Virtual-Care-Enabler (wie Amwell oder KRY/Livi) zur Maximierung der Patientenreichweite und -bindung in der Front-Door-Strategie.Die Verbindung dieser digitalen Basisinfrastruktur mit spezialisierten Lösungen ermöglicht weiterhin einen signifikanten Multiple-Hebel und ist der Schlüssel zur Realisierung der aggressiven operativen Synergien. Für Investoren ist daher ein fundamentales Umdenken erforderlich: Der Fokus muss von isolierten Produktbetrachtungen auf integrierte Plattformstrategien verschoben werden. Interoperabilität und Integrationsfähigkeit sind nicht nur technische, sondern die entscheidenden finanziellen Bewertungskriterien. Die schnelle Positionierung der eigenen Plattform auf Basis hoher Multiples ist die entscheidende wettbewerbsstrategische Herausforderung für alle Marktteilnehmer.'

Nelson Advisors featured in M&A Review: Buy & Build im Healthtech – Warum platform deals das digital health M&A prägen

Nelson Advisors has been invited to mentor and judge the MedTech Innovator 2026 programme alongside a panel of esteemed US and European industry executives. Now in its 13th year, MedTech Innovator, the world’s largest medtech accelerator continues to identify the most promising medical device, diagnostic, and digital health startups developing innovative tools to improve patient care. &nbsp; <a data-mce-href="https://medtechinnovator.org/" href="https://medtechinnovator.org/" title="https://medtechinnovator.org/" target="_blank" rel="noopener">https://medtechinnovator.org/</a> &nbsp; MedTech Innovator is the world's largest accelerator for medical device, digital health, and diagnostic companies. Our mission is to improve patients' lives by accelerating the growth of companies transforming healthcare worldwide. &nbsp; MedTech Innovator is a nonprofit global accelerator and competition platform focused on scaling high-potential medtech startups. &nbsp; Core identity &nbsp; • &nbsp; It is the largest and one of the highest-performing accelerators globally for medical device, digital health, and diagnostic companies, serving as the industry’s premier showcase and competition.&nbsp; &nbsp; • &nbsp;The mission is to improve patients’ lives by accelerating the growth of companies transforming the healthcare system.&nbsp; &nbsp; Programme model and scope &nbsp; • &nbsp;Each year, MedTech Innovator selects 50+ early- and growth-stage startups and scaleups into its accelerator and showcase programs, drawn from a global applicant pool.&nbsp; &nbsp; • &nbsp;The program is remote-friendly and founder-friendly, typically non-dilutive (no equity or fees), and open to companies from early stage up to around Series C.&nbsp; &nbsp; Value proposition for companies• &nbsp;Participants gain tailored mentorship, a structured curriculum, and access to an extensive network of strategics, investors, providers, payers, and regulators such as FDA and NIH.&nbsp; &nbsp;• &nbsp;Startups receive high-profile conference visibility, often at events like The MedTech Conference, and compete for substantial non-dilutive prize funding.&nbsp;

Nelson Advisors invited to Judge MedTech Innovator 2026, the world's largest accelerator for medical device, digital health and diagnostic companies

Looking ahead at the 2026 HealthTech M&amp;A market, Nelson Advisors will continue to guide founders and investors to build and evidence scalable, sustainable and defendable businesses in order to attract strategic buyers and secure high valuation deals. Here is the playbook we deliver week in and week out, grounded in current market dynamics, based on a front row seat view of the industry. &nbsp;&nbsp; Scalable &gt; UK and Europe Prioritise technologies with cross-border potential and operational efficiency.&nbsp; &nbsp; European buyers, including US firms seeking global expansion, are targeting solutions like telehealth, AI-driven diagnostics, and remote patient monitoring (RPM) that can scale across diverse healthcare systems.&nbsp; The UK’s NHS and European integrated care systems (ICSs) are driving demand for interoperable platforms that integrate seamlessly into existing infrastructures.For example, a telehealth platform with proven adoption in the UK could scale into Germany or France by aligning with local regulations and workflows.&nbsp; Founders should demonstrate scalability through a growing user base, low-cost expansion models, and partnerships with regional healthcare providers, capitalising on the trend of increased cross-border deals. Sustainable &gt; UK and Europe &nbsp;&nbsp; Focus on financial resilience and alignment with value-based care.&nbsp; The UK healthtech sector, valued at £34.3 billion annually, has seen a funding pullback since 2021, with digital health investment dropping 34% in 2023 to £835 million.&nbsp; &nbsp;&nbsp; High interest rates and inflation have exposed companies with high burn rates, particularly in overcapitalised segments like niche telehealth.&nbsp; &nbsp;&nbsp; Buyers are prioritising firms with strong revenue growth (20%+ YoY), profitability and recurring revenue models, such as SaaS platforms for patient engagement.&nbsp; &nbsp;&nbsp; For instance, a company offering RPM for chronic disease management with NHS contracts can demonstrate sustainable revenue.&nbsp; &nbsp;&nbsp; Founders should optimise costs, secure long-term payer agreements and target preventive care solutions, which are gaining traction as healthcare systems shift toward outcome-based models. Defendable &gt; UK and Europe &nbsp;&nbsp; Build moats through technology, partnerships, regulatory compliance, and cybersecurity. credentials. &nbsp;&nbsp; Buyers in the UK and Europe value companies with strong intellectual property (IP), such as patented AI algorithms or FDA-cleared devices, which provide competitive barriers.&nbsp; &nbsp;&nbsp; The sector faces intense cybersecurity threats, with breaches costing £1.3 million each in the UK, making robust data protection a priority.&nbsp; &nbsp;&nbsp; Regulatory hurdles, like antitrust scrutiny and evolving telehealth laws, also demand compliance readiness. A healthtech firm with a secure, GDPR-compliant platform and a regulatory roadmap such as a predicate product for clearance, stands out.&nbsp; &nbsp;&nbsp; Deep integration into clinical workflows, like a diagnostics tool embedded in NHS systems, further enhances defensibility by making displacement difficult. &nbsp;&nbsp; Playbook &gt; UK and Europe &nbsp;&nbsp; Target strategic buyers like NHS aligned players or private equity firms seeking to bolster digital capabilities.&nbsp; &nbsp;&nbsp; Showcase key metrics: customer retention, revenue multiples (currently 4-6x for high-quality firms), and clinical outcomes (eg. 25% cost reduction in patient care).&nbsp; De-risk deals by addressing regulatory and cybersecurity concerns upfront, ensuring transparency with audited financials and compliance certifications. Finally, align with market trends like AI, value-based care, and mental health solutions, while avoiding saturated segments like general telehealth, where buyer interest has waned. &nbsp;&nbsp; By focusing on scalability across borders, sustainable financial models, and defendable tech and compliance, healthtech founders in the UK and Europe can navigate the 2025 M&amp;A market and secure premium deals with strategic or financial buyers.

Scalable Sustainable Defendable: The European HealthTech and MedTech M&A Playbook for 2026

Nelson Advisors featured in Helm &amp; Nagel : How AI is Dissolving the Boundaries Between Pharma and MedTech discussing Germany's Healthacre AI convergance.'As artificial intelligence enables unprecedented data integration and collaborative workflows, traditional boundaries between pharmaceutical development and medical technology are being challenged. This transformation is particularly evident in Germany, where an unusual confluence of sectoral strengths creates opportunities for market leadership in AI-driven healthcare innovation.Medical technology companies collaborate with pharmaceutical firms on AI-enhanced clinical trials, major pharmaceutical players integrate real-world evidence from medical devices into drug discovery, and biotech companies develop companion diagnostics alongside therapeutics. These patterns indicate systematic convergence.Germany occupies a unique position at the intersection of three converging forces: world-leading pharmaceutical capabilities, Europe’s largest medical technology sector, and accelerating AI momentum. Realizing this potential requires strategic investment in the intersections between these traditionally separate domains.'Source: <a href="https://helm-nagel.com/en/germanys-healthcare-ai-convergence/" data-mce-href="https://helm-nagel.com/en/germanys-healthcare-ai-convergence/">https://helm-nagel.com/en/germanys-healthcare-ai-convergence/</a>Healthcare.digital. (2025, July 18). European HealthTech, Digital Health and Healthcare AI Exits in 2025: A Mid-Year Analysis and Outlook. Retrieved from <a href="https://www.healthcare.digital/single-post/european-healthtech-digital-health-and-healthcare-ai-exits-in-2025-a-mid-year-analysis-and-outlook" data-mce-href="https://www.healthcare.digital/single-post/european-healthtech-digital-health-and-healthcare-ai-exits-in-2025-a-mid-year-analysis-and-outlook">https://www.healthcare.digital/single-post/european-healthtech-digital-health-and-healthcare-ai-exits-in-2025-a-mid-year-analysis-and-outlook</a>

Nelson Advisors featured in Helm & Nagel : How AI is Dissolving the Boundaries Between Pharma and MedTech

Nelson Advisors research was featured in The M&amp;A Journal: Increasing Exit Multiples: IP and AI Asset Management in M&amp;A Transactions authored by James E. Malackowski and Angelica Hofmann.'The protection and management of intellectual property (IP) assets and artificial intelligence (AI) resources during company sale processes have evolved from ancillary considerations to critical value drivers that can significantly influence EBITDA valuation multiples and overall transaction success. As we witness the completion of the market transition to an economy where intangible assets represent the dominant source of corporate value, the strategic management of IP and AI assets has become paramount in M&amp;A transactions.'Source: <a href="https://www.jsheld.com/uploads/Increasing-Exit-Multiples_IP-and-AI-Asset-Management-in-MA-Transactions-The-MA-Journal-Vol-24-No-8.pdf" data-mce-href="https://www.jsheld.com/uploads/Increasing-Exit-Multiples_IP-and-AI-Asset-Management-in-MA-Transactions-The-MA-Journal-Vol-24-No-8.pdf">https://www.jsheld.com/uploads/Increasing-Exit-Multiples_IP-and-AI-Asset-Management-in-MA-Transactions-The-MA-Journal-Vol-24-No-8.pdf</a>AI-Specific Valuation ImpactsCompanies with proprietary AI models and clean data rights often receive premium valuations, with AI companies commanding median multiples exceeding 25.0x revenue in larger transactions. (8) Healthcare AI companies with proven solutions could see multiples rise to 6-8x revenue, above the sector average of 4.5-5x, reflecting buyers’ willingness to pay premiums for innovation and future revenue potential. (9) Companies relying heavily on third-party AI services or with unclear data ownership face valuation penalties.Source (9) &nbsp;<a href="https://www.healthcare.digital/single-post/healthtech-m-a-multiples-march-2025-current-trends-and-variables-driving-valuations" data-mce-href="https://www.healthcare.digital/single-post/healthtech-m-a-multiples-march-2025-current-trends-and-variables-driving-valuations">https://www.healthcare.digital/single-post/healthtech-m-a-multiples-march-2025-current-trends-and-variables-driving-valuations</a>

Nelson Advisors featured in The M&A Journal: Increasing Exit Multiples: IP and AI Asset Management in M&A Transactions

European healthcare M&amp;A comeback in 2025 lays foundations for robust year aheadEurope’s healthcare M&amp;A is poised to maintain strong momentum in 2026 following this year’s rebound in deal activity and renewed market confidence.“The sector is in a flywheel of productivity with drivers including ageing populations, workforce shortages, and technology adoption,” said Lloyd Price, Partner at Nelson Advisors.Following the turbulent tariff and regulatory environment at the start of 2025, the market is entering a period of relative confidence, he added.&gt;&gt;Pharma searches for blockbustersBiopharma has undeniably been given a turbo-boost by a craze over GLP‑1 agonists for their weight-loss effects as well as downstream protection from cardiovascular disease and diabetes, Price said. Patent cliffs in big pharma pipelines are driving acquisitions of potential new blockbusters, he added.Medical devices and equipment suppliers were an important driver of dealmaking this year as healthcare systems seek to cut labour costs and reduce massive elective care backlogs after the COVID-19 pandemic, Price said.The public healthcare backlog is leading to growth in private healthcare clinics, which then need their own consumables, Price said.Digital health is expected to see strong growth, with “blockbuster” digital health IPOs from US-based Hinge Health and Omada Health holding their prices. This rebuilds confidence in unit economics and profitability in public markets, Price said.&gt;&gt;Cross-border attractionsA weaker pound and euro make European companies effectively cheaper for US buyers than domestic assets, Price said. Combined with improving financial performance, that’s a major draw right now, he added.Indeed, 2025 has seen an increase in inbound M&amp;A, with volumes YTD up by a factor of 2.5 YOY from EUR 7.4bn in 2024 to EUR 18.1bn.AI impact on CROs, CDMOs double-edged sword"People want to catch up with the AI trend. Boards and CEOs are looking to buy a lot of tech and teams, ” Price said, citing ambient voice technology as an example.All in all, with clear fundamentals for dealmaking in place, supported by major demographic and sector digitalisation trends, the European healthcare market can look forward to a solid 2026."We've had 18 months of surprises, so everyone's careful about making the wrong decision. But now the waters are calmer. What are we waiting for?" Price said.Source: <a href="https://mergermarket.ionanalytics.com/content/1004413200?source=news">https://mergermarket.ionanalytics.com/content/1004413200?source=news</a>'European healthcare M&amp;A comeback in 2025 lays foundations for robust year ahead' by Jonathan Smith and Anahita Sawhney.

Nelson Advisors

Blog

Nelson Advisors featured in M&A Review: Buy & Build im He...

Nelson Advisors invited to Judge MedTech Innovator 2026, ...

Scalable Sustainable Defendable: The European HealthTech ...

Nelson Advisors featured in Helm & Nagel : How AI is Diss...

Nelson Advisors featured in The M&A Journal: Increasing E...

Nelson Advisors interviewed by Mergermarket discussing He...